Abstract:TYK2 mediates signaling of IL-23, IL-12, and Type I IFN-driven responses that are critical in immune-mediated diseases. Herein, we report the design, synthesis, and structure–activity relationships (SARs) of 3-(4-(2-((1H-indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile derivatives as selective TYK2 inhibitors. Among them, compound 14l exhibited acceptable TYK2 inhibition with an IC50 value of 9 nM, showed satisfactory selectivity characteristics over the other three homologous JAK kinases, and performed good functional potency in the JAK/STAT signaling pathway on lymphocyte lines and human whole blood. In liver microsomal assay studies, the clearance rate and half-life of 14l were 11.4 mL/min/g and 121.6 min, respectively. Furthermore, in a dextran sulfate sodium colitis model, 14l reduced the production of pro-inflammatory cytokines IL-6 and TNF-α and improved the inflammation symptoms of mucosal infiltration, thickening, and edema. Taken together, 14l was a selective TYK2 inhibitor and could be used to treat immune diseases deserving further investigation.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01468?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01468</a>.11e_in_2XA4_JAK2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_001.pdb">PDB</a>)11e_in_4GJ3_TYK2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_002.pdb">PDB</a>)14l_in_2XA4_JAK2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_003.pdb">PDB</a>)14l_in_4GJ3_TYK2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_004.pdb">PDB</a>)jmcmar_ccc (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_005.xls">XLS</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_006.csv">CSV</a>)Compounds 12a–12g with different hinge binders and their enzymatic potencies (Table S1); enzymatic potencies and the metabolic stability of compounds 13a–13l (Table S2); enzymatic potencies and the metabolic stability of compounds 14a–14o (Table S3); kinome-wide selectivity profiling of compound 14l @ 0.1 μM (Table S4); 1H NMR, 13C NMR, and HRMS-ESI of 14l, respectively (Figures S1–S3); purity of 14l (Figure S4); and biological assay methods (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_007.pdf">PDF</a>)This article has not yet been cited by other publications.

52574 Safety and Efficacy of Selective TYK2/JAK1 Inhibitor, TLL-018, in Moderate-to-severe Plaque Psoriasis

A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways

JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors

Lead identification of novel and selective TYK2 inhibitors

Small-molecule inhibitors of protein kinase C, the Janus kinases (JAK) pathway and phosphodiesterases in the treatment of psoriasis

Novel TYK2 Inhibitors with an N -(Methyl- d 3 )pyridazine-3-carboxamide Skeleton for the Treatment of Autoimmune Diseases.

Discovery of 3-(4-(2-((1 H -Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1 H -pyrazol-1-yl)propanenitrile Derivatives as Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease

Novel TYK2 Inhibitors with an N-(Methyl-d3)pyridazine-3-carboxamide Skeleton for the Treatment of Autoimmune Diseases

Focus on TYK2 Inhibition

Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases

Discovery of 3-(4-(2-((1h-indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1h-pyrazol-1-yl)propanenitrile Derivatives As Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease

Design, Synthesis, and Biological Evaluation of an Orally Bioavailable, Potent, and Selective ROCK2 Inhibitor for Psoriasis Treatment.

Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway

Efficacy and Safety of TLL-018 in Moderate to Severe Chronic Spontaneous Urticaria Patients with Inadequate Response to H1 Antihistamine: Results from a Phase Ib Study

TYK2 inhibition: changing the treatment landscape for psoriasis?

Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-α production in human whole blood

Design, Synthesis, and Pharmacological Evaluation of 4- or 6-Phenyl-pyrimidine Derivatives As Novel and Selective Janus Kinase 3 Inhibitors.

Therapeutic potential of a synthetic dual JAK1/TYK2 inhibitor in inflammatory bowel disease

Design of a potent and selective dual JAK1/TYK2 inhibitor

Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease

Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis